ATAI Life Sciences NV (XETRA:9VC) — Stock Price
ATAI Life Sciences NV (XETRA:9VC) is currently trading at €3.43 EUR, down 1.21% today. Over the past 52 weeks, shares have ranged between €3.11 and €5.49. This page tracks ATAI Life Sciences NV's live share price on the XETRA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see ATAI Life Sciences NV market cap and net worth.
ATAI Life Sciences NV (9VC) Stock Price Chart — Daily History & Trading Volume
The chart below tracks ATAI Life Sciences NV's daily closing share price and trading volume on the XETRA exchange over the past year, giving a clear view of recent price momentum and liquidity.
ATAI Life Sciences NV Income Statement — Revenue, Profit & Earnings by Year
ATAI Life Sciences NV's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | €308.00K | €314.00K | €233.00K | €20.38 Million | €0.00 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | €55.45 Million | €62.20 Million | €74.31 Million | €47.96 Million | €11.41 Million |
| SG&A | €47.54 Million | €63.58 Million | €70.35 Million | €92.75 Million | €80.73 Million |
| Total Operating Expenses | €102.47 Million | €123.34 Million | €144.66 Million | €140.70 Million | €92.14 Million |
| Operating Income | €-102.17 Million | €-123.03 Million | €-144.43 Million | €-120.33 Million | €-92.14 Million |
| EBITDA | — | — | — | — | €-92.12 Million |
| EBIT | — | — | €-144.43 Million | €-120.33 Million | — |
| Interest Expense | €3.12 Million | €2.66 Million | €923.00K | — | — |
| Income Before Tax | €-148.41 Million | €-39.29 Million | €-135.18 Million | €-136.60 Million | €-101.81 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-149.27 Million | €-40.22 Million | €-152.38 Million | €-167.81 Million | €-169.84 Million |
ATAI Life Sciences NV Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes ATAI Life Sciences NV's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | €159.39 Million | €293.48 Million | €305.44 Million | €414.17 Million | €111.55 Million |
| Total Current Assets | €80.12 Million | €185.59 Million | €287.14 Million | €375.08 Million | €99.55 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €44.83 Million | €134.22 Million | €82.50 Million | €0.00 | — |
| Net Receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | €331.00K | €0.00 | — | — | — |
| Total Liabilities | €42.83 Million | €49.16 Million | €39.67 Million | €28.21 Million | €16.18 Million |
| Total Current Liabilities | €24.95 Million | €20.12 Million | €19.90 Million | €20.93 Million | €12.30 Million |
| Long-term Debt | €14.13 Million | €17.88 Million | €15.12 Million | €743.00K | €2.18 Million |
| Net Debt | €5.99 Million | — | — | — | — |
| Total Stockholder Equity | €116.30 Million | €242.96 Million | €260.74 Million | €376.91 Million | €90.82 Million |
| Retained Earnings | €-700.21 Million | €-550.94 Million | €-510.19 Million | €-357.80 Million | €-190.00 Million |
ATAI Life Sciences NV Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how ATAI Life Sciences NV generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-82.44 Million | €-84.12 Million | €-104.47 Million | €-63.25 Million | €-20.77 Million |
| Capital Expenditures | €95.00K | €590.00K | €1.02 Million | €1.13 Million | €59.00K |
| Free Cash Flow | €-82.53 Million | €-84.71 Million | €-105.49 Million | €-64.37 Million | €-20.82 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | €5.37 Million | €-8.36 Million | €20.79 Million | €409.86 Million | €113.05 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €25.49 Million | €32.98 Million | €42.38 Million | €63.36 Million | €67.16 Million |
| Depreciation | €473.00K | €319.00K | €168.00K | €47.00K | €24.00K |
| Change in Cash | €-17.53 Million | €-145.58 Million | €-171.65 Million | €265.02 Million | €67.18 Million |
ATAI Life Sciences NV Earnings History — EPS Actual vs. Analyst Estimates
Track ATAI Life Sciences NV's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 12, 2026 | — | — | — |
| Mar 16, 2026 | — | -0.12 | — |
| Nov 13, 2025 | -0.24 | -0.12 | -100.17% |
| Aug 13, 2025 | -0.12 | -0.12 | -3.67% |
| May 14, 2025 | -0.14 | — | — |
| Mar 26, 2025 | — | — | — |
| Nov 13, 2024 | -0.15 | — | — |
| Aug 13, 2024 | -0.33 | — | — |